Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 +4.86%76 Pretax Margin % is 13.77% as of Dec. 2025, which is 3% above its 10-year median of 13.35. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$19.91 (Fairly Valued). The stock has 7 warning signs investors should review. Among 941 Biotechnology companies, RBC Bioscience ranks better than 81.83% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
RBC Bioscience Pretax Margin % Related Terms
RBC Bioscience Pretax Margin % Historical Data
* Premium members only.
The historical data trend for RBC Bioscience's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, RBC Bioscience's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RBC Bioscience (ROCO:6848) has a Pretax Margin % of 13.77% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on RBC Bioscience and its competitors. This is near median its historical median of 13.35. Over the past decade, RBC Bioscience's Pretax Margin % has ranged from 2.83 to 30.83. According to the industry distribution chart, RBC Bioscience ranks #171 out of 941 companies in the Biotechnology industry, placing it in the top 18.2%.
Is RBC Bioscience's Pretax Margin % too high?
RBC Bioscience's current Pretax Margin % of 13.77% is near median its 10-year median of 13.35. Over the past 10 years, this metric has ranged from a low of 2.83 to a high of 30.83. Based on the distribution chart, RBC Bioscience ranks #171 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #171 out of 941 companies for Pretax Margin %. This places RBC Bioscience in the top 18% of its industry — outperforming the majority of peers. Historically, RBC Bioscience's own Pretax Margin % has ranged from 2.83 to 30.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on RBC Bioscience and its competitors. RBC Bioscience's current Pretax Margin % is 13.77%, which is near median its own 10-year median of 13.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$20.50 — trading 3% above its estimated fair value. The current Pretax Margin % is 13.77%, which is near median its 10-year median of 13.35. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current Pretax Margin % is 13.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$20.50 is trading 3% above its estimated GF Value™ of NT$19.91.
GuruFocus considers RBC Bioscience to be Fairly Valued.
Key valuation signals for ROCO:6848:
Pretax Margin %: 13.77% (near median its 10-year median of 13.35)
GF Value™: NT$19.91 vs. price of NT$20.50 (3% above fair value)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
